Network abnormalities and interneuron dysfunction in Alzheimer disease

Nature Reviews Neuroscience

Volumn 17, Issue 12, 2016, Pages 777-792

  Palop, Jorge J ^a,b   Mucke, Lennart ^a,b  

^a GLADSTONE INSTITUTE OF NEUROLOGICAL DISEASE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; BRAIN ATROPHY; BRAIN FUNCTION; COGNITION; COGNITIVE DEFECT; ELECTROENCEPHALOGRAM; HUMAN; INTERNEURON; LONG TERM DEPRESSION; NERVE CELL NETWORK; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYNAPTIC POTENTIAL; ANIMAL; BRAIN; NERVE TRACT; PATHOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; BRAIN; COGNITION DISORDERS; HUMANS; INTERNEURONS; NERVE NET; NEURAL PATHWAYS;

EID: 84994464103     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn.2016.141     Document Type: Review

References (258)

1. Seidman, L. J. et al. Medial temporal lobe default mode functioning and hippocampal structure as vulnerability indicators for schizophrenia: a MRI study of non-psychotic adolescent first-degree relatives. Schizophr. Res. 159, 426-434 (2014).
2. Fahoum, F., Zelmann, R., Tyvaert, L., Dubeau, F. & Gotman, J. Epileptic discharges affect the default mode network-fMRI and intracerebral EEG evidence. PLoS ONE 8, e68038 (2013).
3. Oser, N. et al. Default mode network alterations during language task performance in children with benign epilepsy with centrotemporal spikes (BECTS). Epilepsy Behav. 33, 12-17 (2014).
4. Sperling, R. A. et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 63, 178-188 (2009).
5. Anticevic, A. et al. The role of default network deactivation in cognition and disease. Trends Cognit. Sci. 16, 584-592 (2012).
6. Filippini, N. et al. Distinct patterns of brain activity in young carriers of the APOE4 allele. Proc. Natl Acad. Sci. USA 106, 7209-7214 (2009).
7. Mondadori, C. R. et al. Enhanced brain activity may precede the diagnosis of Alzheimer's disease by 30 years. Brain 129, 2908-2922 (2006).
8. Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795-804 (2012).
9. Reiman, E. M. et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 11, 1048-1056 (2012).
10. Jasper, H. H. Cortical excitatory state and variability in human brain rhythms. Science 83, 259-260 (1936).
11. Destexhe, A., Contreras, D. & Steriade, M. Spatiotemporal analysis of local field potentials and unit discharges in cat cerebral cortex during natural wake and sleep states. J. Neurosci. 19, 4595-4608 (1999).
12. Poulet, J. F. & Petersen, C. C. Internal brain state regulates membrane potential synchrony in barrel cortex of behaving mice. Nature 454, 881-885 (2008).
13. Poulet, J. F., Fernandez, L. M., Crochet, S. & Petersen, C. C. Thalamic control of cortical states. Nat. Neurosci. 15, 370-372 (2012).
14. Karran, E., Mercken, M. & De Strooper, B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 10, 698-712 (2011).
15. Benilova, I., Karran, E. & De Strooper, B. The toxic A oligomer and Alzheimer's disease: an emperor in need of clothes. Nat. Neurosci. 15, 349-357 (2012).
16. Karch, C. M., Cruchaga, C. & Goate, A. M. Alzheimer's disease genetics: from the bench to the clinic. Neuron 83, 11-26 (2014).
17. Gomez-Isla, T. et al. The impact of different presenilin 1 and presenilin 2 mutations on amyloid deposition, neurofibrillary changes and neuronal loss in the familial Alzheimer's disease brain: evidence for other phenotype-modifying factors. Brain 122, 1709-1719 (1999).
18. Jankowsky, J. L. et al. Mutant presenilins specifically elevate the levels of the 42 residue amyloid peptide in vivo: evidence for augmentation of a 42specific secretase. Hum. Mol. Genet. 13, 159-170 (2004).
19. Steiner, H. & Haass, C. Intramembrane proteolysis by presenilins. Nat. Rev. Mol. Cell Biol. 1, 217-224 (2000).
20. Tsubuki, S., Takaki, Y. & Saido, T. C. Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of A to physiologically relevant proteolytic degradation. Lancet 361, 1957-1958 (2003).
21. Nilsberth, C. et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced A protofibril formation. Nat. Neurosci. 4, 887-893 (2001).
22. Shimada, H. et al. Clinical course of patients with familial early-onset Alzheimer's disease potentially lacking senile plaques bearing the E693 mutation in amyloid precursor protein. Dement. Geriatr. Cogn. Disord. 32, 45-54 (2011).
23. Jonsson, T. et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96-99 (2012).
24. Maloney, J. A. et al. Molecular mechanisms of Alzheimer disease protection by the A673T allele of amyloid precursor protein. J. Biol. Chem. 289, 30990-31000 (2014).
25. Li, S. et al. Soluble oligomers of amyloid protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62, 788-801 (2009).
26. Shankar, G. M. et al. Amyloid protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842 (2008).
27. Li, S. et al. Soluble A oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2Bcontaining NMDA receptors. J. Neurosci. 31, 6627-6638 (2011).
28. Cleary, J. P. et al. Natural oligomers of the amyloid protein specifically disrupt cognitive function. Nat. Neurosci. 8, 79-84 (2005).
29. Musiek, E. S. & Holtzman, D. M. Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. Nat. Neurosci. 18, 800-806 (2015).
30. Liu, P. et al. Quaternary structure defines a large class of amyloid oligomers neutralized by sequestration. Cell Rep. 11, 1760-1771 (2015).
31. Ashe, K. H. & Zahs, K. R. Probing the biology of Alzheimer's disease in mice. Neuron 66, 631-645 (2010).
32. Morris, M., Maeda, S., Vossel, K. & Mucke, L. The many faces of tau. Neuron 70, 410-426 (2011).
33. Huang, Y. & Mucke, L. Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204-1222 (2012).
34. Heppner, F. L., Ransohoff, R. M. & Becher, B. Immune attack: the role of inflammation in Alzheimer disease. Nat. Rev. Neurosci. 16, 358-372 (2015).
35. Maeda, S. et al. Expression of A152T human tau causes age-dependent neuronal dysfunction and loss in transgenic mice. EMBO Rep. 17, 530-551 (2016).
36. SantaCruz, K. et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481 (2005).
37. Mandelkow, E. M. & Mandelkow, E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb. Perspect. Med. 2, a006247 (2012).
38. Min, S. W. et al. Critical role of acetylation in taumediated neurodegeneration and cognitive deficits. Nat. Med. 21, 1154-1162 (2015).
39. Mahley, R. W. & Huang, Y. Apolipoprotein E sets the stage: response to injury triggers neuropathology. Neuron 76, 871-885 (2012).
40. Pike, K. E. et al. Amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130, 2837-2844 (2007).
41. Savva, G. M. et al. Age, neuropathology, and dementia. N. Engl. J. Med. 360, 2302-2309 (2009).
42. Ingelsson, M. et al. Early A accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62, 925-931 (2004).
43. Lesne, S. E. et al. Brain amyloid oligomers in ageing and Alzheimer's disease. Brain 136, 1383-1398 (2013).
44. Selkoe, D. J. Soluble oligomers of the amyloid protein impair synaptic plasticity and behavior. Behav. Brain Res. 192, 106-113 (2008).
45. Klein, W. L., Krafft, G. A. & Finch, C. E. Targeting small A oligomers: the solution to an Alzheimer's disease conundrum. Trends Neurosci. 24, 219-224 (2001).
46. Walsh, D. M. & Selkoe, D. J. A oligomers-a decade of discovery. J. Neurochem. 101, 1172-1184 (2007).
47. Shankar, G. M. et al. Natural oligomers of the Alzheimer amyloid protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27, 2866-2875 (2007).
48. Cheng, I. H. et al. Accelerating amyloid-fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J. Biol. Chem. 282, 23818-23828 (2007).
49. Tomiyama, T. et al. A mouse model of amyloid oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J. Neurosci. 30, 4845-4856 (2010).
50. Lesné, S. et al. A specific amyloid protein assembly in the brain impairs memory. Nature 440, 352-357 (2006).
51. Meilandt, W. J. et al. Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic A oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J. Neurosci. 29, 1977-1986 (2009).
52. Mably, A. J. et al. Anti-A antibodies incapable of reducing cerebral A oligomers fail to attenuate spatial reference memory deficits in J20 mice. Neurobiol. Dis. 82, 372-384 (2015).
53. De Strooper, B. Lossoffunction presenilin mutations in Alzheimer disease. EMBO Rep. 8, 141-146 (2007).
54. Pimplikar, S. W. Neuroinflammation in Alzheimer's disease: from pathogenesis to a therapeutic target. J. Clin. Immunol. 34, S64-S69 (2014).
55. Xia, D. et al. Presenilin1 knockin mice reveal lossoffunction mechanism for familial Alzheimer's disease. Neuron 85, 967-981 (2015).
56. Bredesen, D. E. Neurodegeneration in Alzheimer's disease: caspases and synaptic element interdependence. Mol. Neurodegener. 4, 27 (2009).
57. Bentley, W. J., Li, J. M., Snyder, A. Z., Raichle, M. E. & Snyder, L. H. Oxygen level and LFP in task-positive and task-negative areas: bridging BOLD fMRI and electrophysiology. Cereb. Cortex 26, 346-357 (2014).
58. Boyatzis, R. E., Rochford, K. & Jack, A. I. Antagonistic neural networks underlying differentiated leadership roles. Front. Hum. Neurosci. 8, 114 (2014).
59. Raichle, M. E. et al. A default mode of brain function. Proc. Natl Acad. Sci. USA 98, 676-682 (2001).
60. Greicius, M. D., Krasnow, B., Reiss, A. L. & Menon, V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc. Natl Acad. Sci. USA 100, 253-258 (2003).
61. Sperling, R. A. et al. Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med. 12, 27-43 (2010).
62. Bookheimer, S. Y. et al. Patterns of brain activation in people at risk for Alzheimer's disease. N. Engl. J. Med. 343, 450-456 (2000).
63. Trivedi, M. A. et al. fMRI activation during episodic encoding and metacognitive appraisal across the lifespan: risk factors for Alzheimer's disease. Neuropsychologia 46, 1667-1678 (2008).
64. Kunz, L. et al. Reduced grid-cell-like representations in adults at genetic risk for Alzheimer's disease. Science 350, 430-433 (2015).
65. Quiroz, Y. T. et al. Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease. Ann. Neurol. 68, 865-875 (2010).
66. Sepulveda-Falla, D., Glatzel, M. & Lopera, F. Phenotypic profile of early-onset familial Alzheimer's disease caused by presenilin1 E280A mutation. J. Alzheimers Dis. 32, 1-12 (2012).
67. Bakker, A. et al. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron 74, 467-474 (2012).
68. Dickerson, B. C. et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology 65, 404-411 (2005).
69. Celone, K. A. et al. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J. Neurosci. 26, 10222-10231 (2006).
70. Persson, J. et al. Altered deactivation in individuals with genetic risk for Alzheimer's disease. Neuropsychologia 46, 1679-1687 (2008).
71. Dickerson, B. C. et al. Medial temporal lobe function and structure in mild cognitive impairment. Ann. Neurol. 56, 27-35 (2004).
72. Putcha, D. et al. Hippocampal hyperactivation associated with cortical thinning in Alzheimer's disease signature regions in non-demented elderly adults. J. Neurosci. 31, 17680-17688 (2011).
73. Bakker, A., Albert, M. S., Krauss, G., Speck, C. L. & Gallagher, M. Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention asessed by fMRI and memory task performance. Neuroimage Clin. 7, 688-698 (2015).
74. Sanchez, P. E. et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc. Natl Acad. Sci. USA 109, E2895-E2903 (2012).
75. Nygaard, H. B. et al. Brivaracetam, but not ethosuximide, reverses memory impairments in an Alzheimer's disease mouse model. Alzheimers Res. Ther. 7, 25 (2015).
76. Suberbielle, E. et al. Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by amyloid. Nat. Neurosci. 16, 613-621 (2013).
77. Suberbielle, E. et al. DNA repair factor BRCA1 depletion occurs in Alzheimer brains and impairs cognitive function in mice. Nat. Commun. 6, 8897 (2015).
78. Madabhushi, R., Pan, L. & Tsai, L. H. DNA damage and its links to neurodegeneration. Neuron 83, 266-282 (2014).
79. Kim, J., Basak, J. M. & Holtzman, D. M. The role of apolipoprotein E in Alzheimer's disease. Neuron 63, 287-303 (2009).
80. Saito, T. et al. Single App knockin mouse models of Alzheimer's disease. Nat. Neurosci. 17, 661-663 (2014).
81. Roh, J. H. et al. Disruption of the sleep-wake cycle and diurnal fluctuation of amyloid in mice with Alzheimer's disease pathology. Sci. Transl Med. 4, 150ra122 (2012).
82. Kang, J. E. et al. Amyloid-dynamics are regulated by orexin and the sleep-wake cycle. Science 326, 1005-1007 (2009).
83. Xie, L. et al. Sleep drives metabolite clearance from the adult brain. Science 342, 373-377 (2013).
84. Bero, A. W. et al. Neuronal activity regulates the regional vulnerability to amyloid-deposition. Nat. Neurosci. 14, 750-756 (2011).
85. Yamamoto, K. et al. Chronic optogenetic activation augments A pathology in a mouse model of Alzheimer disease. Cell Rep. 11, 859-865 (2015).
86. Dolev, I. et al. Spike bursts increase amyloid-40/42 ratio by inducing a presenilin conformational change. Nat. Neurosci. 16, 587-595 (2013).
87. Nitsch, R. M., Farber, S. A., Growdon, H. J. & Wurtman, R. J. Release of amyloid protein precursor derivatives by electrical depolarization of rat hippocampal slices. Proc. Natl Acad. Sci. USA 90, 5191-5193 (1993).
88. Kamenetz, F. et al. APP processing and synaptic function. Neuron 37, 925-937 (2003).
89. Abbott, L. F. & Regehr, W. G. Synaptic computation. Nature 431, 796-803 (2004).
90. Laviv, T. et al. Basal GABA regulates GABABR conformation and release probability at single hippocampal synapses. Neuron 67, 253-267 (2010).
91. Palop, J. J. & Mucke, L. Amyloid-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 13, 812-818 (2010).
92. Cirrito, J. R. et al. Synaptic activity regulates interstitial fluid amyloid levels in vivo. Neuron 48, 913-922 (2005).
93. Abramov, E. et al. Amyloid as a positive endogenous regulator of release probability at hippocampal synapses. Nat. Neurosci. 12, 1567-1576 (2009).
94. Puzzo, D. et al. Picomolar amyloid-positively modulates synaptic plasticity and memory in hippocampus. J. Neurosci. 28, 14537-14545 (2008).
95. Willem, M. et al. Secretase processing of APP inhibits neuronal activity in the hippocampus. Nature 526, 443-447 (2015).
96. Palop, J. J. et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55, 697-711 (2007).
97. Yang, X. F., Weisenfeld, A. & Rothman, S. M. Prolonged exposure to levetiracetam reveals a presynaptic effect on neurotransmission. Epilepsia 48, 1861-1869 (2007).
98. Meehan, A. L., Yang, X., McAdams, B. D., Yuan, L. & Rothman, S. M. A new mechanism for antiepileptic drug action: vesicular entry may mediate the effects of levetiracetam. J. Neurophysiol. 106, 1227-1239 (2011).
99. Kurudenkandy, F. R. et al. Amyloid-induced action potential desynchronization and degradation of hippocampal gamma oscillations is prevented by interference with peptide conformation change and aggregation. J. Neurosci. 34, 11416-11425 (2014).
100. Sanchez-Mejia, R. O. et al. Phospholipase A2 reduction ameliorates cognitve deficits in mouse model of Alzheimer's disease. Nat. Neurosci. 11, 1311-1318 (2008).
101. Busche, M. A. et al. Critical role of soluble amyloid for early hippocampal hyperactivity in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 109, 8740-8745 (2012).
102. Minkeviciene, R. et al. Amyloid induced neuronal hyperexcitability triggers progressive epilepsy. J. Neurosci. 29, 3453-3462 (2009).
103. Um, J. W. et al. Alzheimer amyloid-oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat. Neurosci. 15, 1227-1235 (2012).
104. Bezzina, C. et al. Early onset of hypersynchronous network activity and expression of a marker of chronic seizures in the Tg2576 mouse model of Alzheimer's disease. PLoS ONE 10, e0119910 (2015).
105. Harris, J. A. et al. Transsynaptic progression of amyloid-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron 68, 428-441 (2010).
106. Born, H. A. et al. Genetic suppression of transgenic APP rescues hypersynchronous network activity in a mouse model of Alzeimer's disease. J. Neurosci. 34, 3826-3840 (2014).
107. Ittner, A. A., Gladbach, A., Bertz, J., Suh, L. S. & Ittner, L. M. p38 MAP kinase-mediated NMDA receptor-dependent suppression of hippocampal hypersynchronicity in a mouse model of Alzheimer inverted question marks disease. Acta Neuropathol. Commun. 2, 149 (2014).
108. Roberson, E. D. et al. Amyloid/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci. 31, 700-711 (2011).
109. Busche, M. A. et al. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science 321, 1686-1689 (2008).
110. Roberson, E. D. et al. Reducing endogenous tau ameliorates amyloid induced deficits in an Alzheimer's disease mouse model. Science 316, 750-754 (2007).
111. Ittner, L. M. et al. Dendritic function of tau mediates amyloid-toxicity in Alzheimer's disease mouse models. Cell 142, 387-397 (2010).
112. Palop, J. J. et al. Vulnerability of dentate granule cells to disruption of Arc expression in human amyloid precursor protein transgenic mice. J. Neurosci. 25, 9686-9693 (2005).
113. Chin, J. et al. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 25, 9694-9703 (2005).
114. Grienberger, C. et al. Staged decline of neuronal function in vivo in an animal model of Alzheimer's disease. Nat. Commun. 3, 774 (2012).
115. Rudinskiy, N. et al. Orchestrated experience-driven Arc responses are disrupted in a mouse model of Alzheimer's disease. Nat. Neurosci. 15, 1422-1429 (2012).
116. Spires, T. L. & Hyman, B. T. Neuronal structure is altered by amyloid plaques. Rev. Neurosci. 15, 267-278 (2004).
117. Koffie, R. M. et al. Oligomeric amyloid associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl Acad. Sci. USA 106, 4012-4017 (2009).
118. Siskova, Z. et al. Dendritic structural degeneration is functionally linked to cellular hyperexcitability in a mouse model of Alzheimer's disease. Neuron 84, 1023-1033 (2014).
119. Garcia-Cabrero, A. M. et al. Hyperexcitability and epileptic seizures in a model of frontotemporal dementia. Neurobiol. Dis. 58, 200-208 (2013).
120. Hunter, J. M. et al. Emergence of a seizure phenotype in aged apolipoprotein epsilon 4 targeted replacement mice. Brain Res. 1467, 120-132 (2012).
121. Morris, M. et al. Network dysfunction in synuclein transgenic mice and human Lewy body dementia. Ann. Clin. Transl Neurol. 2, 1012-1028 (2015).
122. Siwek, M. E. et al. Altered theta oscillations and aberrant cortical excitatory activity in the 5XFAD model of Alzheimer's disease. Neural Plast. 2015, 781731 (2015).
123. Lalonde, R., Dumont, M., Staufenbiel, M. & Strazielle, C. Neurobehavioral characterization of APP23 transgenic mice with the SHIRPA primary screen. Behav. Brain Res. 157, 91-98 (2005).
124. Hsiao, K. K. et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 15, 1203-1218 (1995).
125. Vossel, K. A. et al. Tau reduction prevents Ainduced impairments in axonal transport. Science 330, 198 (2010).
126. Devos, S. L. et al. Antisense reduction of tau in adult mice protects against seizures. J. Neurosci. 33, 12887-12897 (2013).
127. Romanelli, M. F., Morris, J. C., Ashkin, K. & Coben, L. A. Advanced Alzheimer's disease is a risk factor for lateonset seizures. Arch. Neurol. 47, 847-850 (1990).
128. Hauser, W. A., Morris, M. L., Heston, L. L. & Anderson, V. E. Seizures and myoclonus in patients with Alzheimer's disease. Neurology 36, 1226-1230 (1986).
129. Irizarry, M. C. et al. Incidence of new-onset seizures in mild to moderate Alzheimer disease. Arch. Neurol. 69, 368-372 (2012).
130. Risse, S. C. et al. Myoclonus, seizures, and paratonia in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 4, 217-225 (1990).
131. Horvath, A., Szucs, A., Barcs, G., Noebels, J. L. & Kamondi, A. Epileptic seizures in Alzheimer disease: a review. Alzheimer Dis. Assoc. Disord. 30, 186-192 (2016).
132. Imfeld, P., Bodmer, M., Schuerch, M., Jick, S. S. & Meier, C. R. Seizures in patients with Alzheimer's disease or vascular dementia: a population-based nested case-control analysis. Epilepsia 54, 700-707 (2013).
133. Amatniek, J. C. et al. Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia 47, 867-872 (2006).
134. Sherzai, D., Losey, T., Vega, S. & Sherzai, A. Seizures and dementia in the elderly: Nationwide Inpatient Sample 1999-2008. Epilepsy Behav. 36, 53-56 (2014).
135. Scarmeas, N. et al. Seizures in Alzheimer disease: who, when, and how common? Arch. Neurol. 66, 992-997 (2009).
136. Vossel, K. A. et al. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol. 70, 1158-1166 (2013).
137. Hesdorffer, D. C., Hauser, W. A., Annegers, J. F., Kokmen, E. & Rocca, W. A. Dementia and adult-onset unprovoked seizures. Neurology 46, 727-730 (1996).
138. Cretin, B. et al. Epileptic prodromal Alzheimer's disease, a retrospective study of 13 new cases: expanding the spectrum of Alzheimer's disease to an epileptic variant? J. Alzheimers Dis. 52, 1125-1133 (2016).
139. Palop, J. J. & Mucke, L. Epilepsy and cognitive impairments in Alzheimer disease. Arch. Neurol. 66, 435-440 (2009).
140. Noebels, J. A perfect storm: converging paths of epilepsy and Alzheimer's dementia intersect in the hippocampal formation. Epilepsia 52 (Suppl. 1), 39-46 (2011).
141. Larner, A. J. Presenilin1 mutation Alzheimer's disease: a genetic epilepsy syndrome Epilepsy Behav. 21, 20-22 (2011).
142. Larner, A. J. & Doran, M. Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin1 gene. J. Neurol. 253, 139-158 (2006).
143. Jayadev, S. et al. Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. Brain 133, 1143-1154 (2010).
144. Cabrejo, L. et al. Phenotype associated with APP duplication in five families. Brain 129, 2966-2976 (2006).
145. McNaughton, D. et al. Duplication of amyloid precursor protein (APP), but not prion protein (PRNP) gene is a significant cause of early onset dementia in a large UK series. Neurobiol. Aging 33, e13-21 (2012).
146. Zarea, A. et al. Seizures in dominantly inherited Alzheimer disease. Neurology 87, 912-919 (2016).
147. Lai, F. & Williams, R. S. A prospective study of Alzheimer disease in Down syndrome. Arch. Neurol. 46, 849-853 (1989).
148. Snider, B. J. et al. Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. Arch. Neurol. 62, 1821-1830 (2005).
149. Moehlmann, T. et al. Presenilin1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on A42 production. Proc. Natl Acad. Sci. USA 99, 8025-8030 (2002).
150. Jensen, O. & Colgin, L. L. Cross-frequency coupling between neuronal oscillations. Trends Cognit. Sci. 11, 267-269 (2007).
151. Viney, T. J. et al. Network state-dependent inhibition of identified hippocampal CA3 axo-axonic cells in vivo. Nat. Neurosci. 16, 1802-1811 (2013).
152. Tukker, J. J., Fuentealba, P., Hartwich, K., Somogyi, P. & Klausberger, T. Cell type-specific tuning of hippocampal interneuron firing during gamma oscillations in vivo. J. Neurosci. 27, 8184-8189 (2007).
153. Uhlhaas, P. J. et al. Neural synchrony in cortical networks: history, concept and current status. Front. Integr. Neurosci. 3, 17 (2009).
154. Matsumoto, J. Y. et al. Network oscillations modulate interictal epileptiform spike rate during human memory. Brain 136, 2444-2456 (2013).
155. Sederberg, P. B. et al. Gamma oscillations distinguish true from false memories. Psychol. Sci. 18, 927-932 (2007).
156. Sederberg, P. B. et al. Hippocampal and neocortical gamma oscillations predict memory formation in humans. Cereb. Cortex 17, 1190-1196 (2007).
157. Jensen, O., Kaiser, J. & Lachaux, J. P. Human gammafrequency oscillations associated with attention and memory. Trends Neurosci. 30, 317-324 (2007).
158. Yamamoto, J., Suh, J., Takeuchi, D. & Tonegawa, S. Successful execution of working memory linked to synchronized high-frequency gamma oscillations. Cell 157, 845-857 (2014).
159. Tallon-Baudry, C., Bertrand, O., Delpuech, C. & Pernier, J. Stimulus specificity of phase-locked and non-phase-locked 40 Hz visual responses in human. J. Neurosci. 16, 4240-4249 (1996).
160. Lachaux, J. P. et al. The many faces of the gamma band response to complex visual stimuli. Neuroimage 25, 491-501 (2005).
161. Harris, K. D. & Thiele, A. Cortical state and attention. Nat. Rev. Neurosci. 12, 509-523 (2011).
162. Crone, N. E., Miglioretti, D. L., Gordon, B. & Lesser, R. P. Functional mapping of human sensorimotor cortex with electrocorticographic spectral analysis. II. Event-related synchronization in the gamma band. Brain 121, 2301-2315 (1998).
163. Burke, J. F. et al. Synchronous and asynchronous theta and gamma activity during episodic memory formation. J. Neurosci. 33, 292-304 (2013).
164. Sun, L. et al. Evidence for dysregulated high-frequency oscillations during sensory processing in medicationnaive, first episode schizophrenia. Schizophr. Res. 150, 519-525 (2013).
165. Herrmann, C. S. & Demiralp, T. Human EEG gamma oscillations in neuropsychiatric disorders. Clin. Neurophysiol. 116, 2719-2733 (2005).
166. Niessing, J. et al. Hemodynamic signals correlate tightly with synchronized gamma oscillations. Science 309, 948-951 (2005).
167. Logothetis, N. K., Pauls, J., Augath, M., Trinath, T. & Oeltermann, A. Neurophysiological investigation of the basis of the fMRI signal. Nature 412, 150-157 (2001).
168. Goldman, R. I., Stern, J. M., Engel, J. Jr & Cohen, M. S. Simultaneous EEG and fMRI of the alpha rhythm. Neuroreport 13, 2487-2492 (2002).
169. Laufs, H. et al. EEG-correlated fMRI of human alpha activity. Neuroimage 19, 1463-1476 (2003).
170. Scheeringa, R. et al. Trialbytrial coupling between EEG and BOLD identifies networks related to alpha and theta EEG power increases during working memory maintenance. Neuroimage 44, 1224-1238 (2009).
171. Ossandon, T. et al. Transient suppression of broadband gamma power in the default-mode network is correlated with task complexity and subject performance. J. Neurosci. 31, 14521-14530 (2011).
172. Verret, L. et al. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 149, 708-721 (2012).
173. Maheshwari, A., Marks, R. L., Yu, K. M. & Noebels, J. L. Shift in interictal relative gamma power as a novel biomarker for drug response in two mouse models of absence epilepsy. Epilepsia 57, 79-88 (2016).
174. Crooks, V. C., Lubben, J., Petitti, D. B., Little, D. & Chiu, V. Social network, cognitive function, and dementia incidence among elderly women. Am. J. Public Health 98, 1221-1227 (2008).
175. Buzsaki, G. & Draguhn, A. Neuronal oscillations in cortical networks. Science 304, 1926-1929 (2004).
176. Hestrin, S. & Galarreta, M. Electrical synapses define networks of neocortical GABAergic neurons. Trends Neurosci. 28, 304-309 (2005).
177. Lapray, D. et al. Behavior-dependent specialization of identified hippocampal interneurons. Nat. Neurosci. 15, 1265-1271 (2012).
178. Fu, Y. et al. A cortical circuit for gain control by behavioral state. Cell 156, 1139-1152 (2014).
179. Sohal, V. S., Zhang, F., Yizhar, O. & Deisseroth, K. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature 459, 698-702 (2009).
180. Fazzari, P. et al. Control of cortical GABA circuitry development by Nrg1 and ErbB4 signalling. Nature 464, 1376-1380 (2010).
181. Kepecs, A. & Fishell, G. Interneuron cell types are fit to function. Nature 505, 318-326 (2014).
182. Southwell, D. G. et al. Interneurons from embryonic development to cell-based therapy. Science 344, 1240622 (2014).
183. Han, S. et al. Autistic-like behaviour in Scn1a+/mice and rescue by enhanced GABA-mediated neurotransmission. Nature 489, 385-390 (2012).
184. Chao, H. T. et al. Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 468, 263-269 (2010).
185. Hunt, R. F., Girskis, K. M., Rubenstein, J. L., Alvarez-Buylla, A. & Baraban, S. C. GABA progenitors grafted into the adult epileptic brain control seizures and abnormal behavior. Nat. Neurosci. 16, 692-697 (2013).
186. Tong, L. M. et al. Inhibitory interneuron progenitor transplantation restores normal learning and memory in ApoE4 knockin mice without or with A accumulation. J. Neurosci. 34, 9506-9515 (2014).
187. Freund, T. F. & Katona, I. Perisomatic inhibition. Neuron 56, 33-42 (2007).
188. Schmidt, M. J. et al. Modulation of behavioral networks by selective interneuronal inactivation. Mol. Psychiatry 19, 580-587 (2014).
189. Kvitsiani, D. et al. Distinct behavioural and network correlates of two interneuron types in prefrontal cortex. Nature 498, 363-366 (2013).
190. Cardin, J. A. et al. Driving fast-spiking cells induces gamma rhythm and controls sensory responses. Nature 459, 663-667 (2009).
191. Cramer, P. E. et al. ApoE-directed therapeutics rapidly clear amyloid and reverse deficits in AD mouse models. Science 335, 1503-1506 (2012).
192. Rubio, S. E. et al. Accelerated aging of the GABAergic septohippocampal pathway and decreased hippocampal rhythms in a mouse model of Alzheimer's disease. FASEB J. 26, 4458-4467 (2012).
193. Gurevicius, K., Lipponen, A. & Tanila, H. Increased cortical and thalamic excitability in freely moving APPswe/PS1dE9 mice modeling epileptic activity associated with Alzheimer's disease. Cereb. Cortex 23, 1148-1158 (2013).
194. Kemere, C., Carr, M. F., Karlsson, M. P. & Frank, L. M. Rapid and continuous modulation of hippocampal network state during exploration of new places. PLoS ONE 8, e73114 (2013).
195. Busche, M. A. et al. Rescue of long-range circuit dysfunction in Alzheimer's disease models. Nat. Neurosci. 18, 1623-1630 (2015).
196. Mander, B. A. et al. Amyloid disrupts human NREM slow waves and related hippocampus-dependent memory consolidation. Nat. Neurosci. 18, 1051-1057 (2015).
197. van Deursen, J. A., Vuurman, E. F., van Kranen-Mastenbroek, V. H., Verhey, F. R. & Riedel, W. J. 40Hz steady state response in Alzheimer's disease and mild cognitive impairment. Neurobiol. Aging 32, 24-30 (2011).
198. van Deursen, J. A., Vuurman, E. F., Verhey, F. R., van Kranen-Mastenbroek, V. H. & Riedel, W. J. Increased EEG gamma band activity in Alzheimer's disease and mild cognitive impairment. J. Neural Transm. (Vienna) 115, 1301-1311 (2008).
199. Nimmrich, V., Draguhn, A. & Axmacher, N. Neuronal network oscillations in neurodegenerative diseases. Neuromolecular Med. 17, 270-284 (2015).
200. Gillespie, A. K. et al. Apolipoprotein E4 causes agedependent disruption of slow gamma oscillations during hippocampal sharp-wave ripples. Neuron 90, 740-751 (2016).
201. Pena-Ortega, F., Solis-Cisneros, A., Ordaz, B., Balleza-Tapia, H. & Javier Lopez-Guerrero, J. Amyloid beta 1-42 inhibits entorhinal cortex activity in the betagamma range: role of GSK3. Curr. Alzheimer Res. 9, 857-863 (2012).
202. Driver, J. E. et al. Impairment of hippocampal gammafrequency oscillations in vitro in mice overexpressing human amyloid precursor protein (APP). Eur. J. Neurosci. 26, 1280-1288 (2007).
203. Villette, V. et al. Decreased rhythmic GABAergic septal activity and memory-associated theta oscillations after hippocampal amyloid-pathology in the rat. J. Neurosci. 30, 10991-11003 (2010).
204. Royer, S. et al. Control of timing, rate and bursts of hippocampal place cells by dendritic and somatic inhibition. Nat. Neurosci. 15, 769-775 (2012).
205. Tort, A. B., Komorowski, R. W., Manns, J. R., Kopell, N. J. & Eichenbaum, H. Theta-gamma coupling increases during the learning of item-context associations. Proc. Natl Acad. Sci. USA 106, 20942-20947 (2009).
206. Lakatos, P., Karmos, G., Mehta, A. D., Ulbert, I. & Schroeder, C. E. Entrainment of neuronal oscillations as a mechanism of attentional selection. Science 320, 110-113 (2008).
207. Canolty, R. T. et al. High gamma power is phase-locked to theta oscillations in human neocortex. Science 313, 1626-1628 (2006).
208. Bragin, A. et al. Gamma (40-100 Hz) oscillation in the hippocampus of the behaving rat. J. Neurosci. 15, 47-60 (1995).
209. Sirota, A. et al. Entrainment of neocortical neurons and gamma oscillations by the hippocampal theta rhythm. Neuron 60, 683-697 (2008).
210. Freund, T. F. Interneuron diversity series: rhythm and mood in perisomatic inhibition. Trends Neurosci. 26, 489-495 (2003).
211. Belluscio, M. A., Mizuseki, K., Schmidt, R., Kempter, R. & Buzsaki, G. Cross-frequency phase-phase coupling between theta and gamma oscillations in the hippocampus. J. Neurosci. 32, 423-435 (2012).
212. Goutagny, R. et al. Alterations in hippocampal network oscillations and theta-gamma coupling arise before A overproduction in a mouse model of Alzheimer's disease. Eur. J. Neurosci. 37, 1896-1902 (2013).
213. Klausberger, T. et al. Brain-state-and cell-type-specific firing of hippocampal interneurons in vivo. Nature 421, 844-848 (2003).
214. Andrews-Zwilling, Y. et al. Hilar GABAergic interneuron activity controls spatial learning and memory retrieval. PLoS ONE 7, e40555 (2012).
215. Wang, W. Z. et al. The developmental changes of Nav1.1 and Nav1.2 expression in the human hippocampus and temporal lobe. Brain Res. 1389, 61-70 (2011).
216. Corbett, B. F. et al. Sodium channel cleavage is associated with aberrant neuronal activity and cognitive deficits in a mouse model of Alzheimer's disease. J. Neurosci. 33, 7020-7026 (2013).
217. Kim, D. Y. et al. BACE1 regulates voltage-gated sodium channels and neuronal activity. Nat. Cell Biol. 9, 755-764 (2007).
218. Yang, L. B. et al. Elevated secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat. Med. 9, 3-4 (2003).
219. Kim, D. Y. et al. The E280A presenilin mutation reduces voltage-gated sodium channel levels in neuronal cells. Neurodegener. Dis. 13, 64-68 (2014).
220. Ponomareva, N. V., Korovaitseva, G. I. & Rogaev, E. I. EEG alterations in non-demented individuals related to apolipoprotein E genotype and to risk of Alzheimer disease. Neurobiol. Aging 29, 819-827 (2008).
221. Andrews-Zwilling, Y. et al. Apolipoprotein E4 causes age-and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice. J. Neurosci. 30, 13707-13717 (2010).
222. Terry, R. D. et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572-580 (1991).
223. DeKosky, S. T. & Scheff, S. W. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann. Neurol. 27, 457-464 (1990).
224. Walsh, D. M. et al. Naturally secreted oligomers of amyloid protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539 (2002).
225. Hsia, A. Y. et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl Acad. Sci. USA 96, 3228-3233 (1999).
226. Mucke, L. et al. High-level neuronal expression of A1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050-4058 (2000).
227. Kim, J. H., Anwyl, R., Suh, Y. H., Djamgoz, M. B. & Rowan, M. J. Use-dependent effects of amyloidogenic fragments of amyloid precursor protein on synaptic plasticity in rat hippocampus in vivo. J. Neurosci. 21, 1327-1333 (2001).
228. Hsieh, H. et al. AMPAR removal underlies A induced synaptic depression and dendritic spine loss. Neuron 52, 831-843 (2006).
229. Palop, J. J. & Mucke, L. Synaptic depression and aberrant excitatory network activity in Alzheimer's disease: two faces of the same coin? Neuromolecular Med. 12, 48-55 (2010).
230. Liu, L. et al. Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science 304, 1021-1024 (2004).
231. Campbell, S. L., Hablitz, J. J. & Olsen, M. L. Functional changes in glutamate transporters and astrocyte biophysical properties in a rodent model of focal cortical dysplasia. Front. Cell. Neurosci. 8, 425 (2014).
232. Palop, J. J. et al. Neuronal depletion of calciumdependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc. Natl Acad. Sci. USA 100, 9572-9577 (2003).
233. Cheng, J. S. et al. Collagen VI protects neurons against A toxicity. Nat. Neurosci. 12, 119-121 (2009).
234. Chin, J. et al. Reelin depletion in the entorhinal cortex of human amyloid precursor protein transgenic mice and humans with Alzheimer's disease. J. Neurosci. 27, 2727-2733 (2007).
235. Meilandt, W. J. et al. Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 28, 5007-5017 (2008).
236. Orr, A. G. et al. Astrocytic adenosine receptor A2A and Gs coupled signaling regulate memory. Nat. Neurosci. 18, 423-434 (2015).
237. Albert, M. S. et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 270-279 (2011).
238. Gainotti, G., Quaranta, D., Vita, M. G. & Marra, C. Neuropsychological predictors of conversion from mild cognitive impairment to Alzheimer's disease. J. Alzheimers Dis. 38, 481-495 (2014).
239. Budson, A. E. & Solomon, P. R. New criteria for Alzheimer disease and mild cognitive impairment: implications for the practicing clinician. Neurologist 18, 356-363 (2012).
240. Jensen, H. S., Grunnet, M. & Bastlund, J. F. Therapeutic potential of NaV1.1 activators. Trends Pharmacol. Sci. 35, 113-118 (2014).
241. Tuszynski, M. H. et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 11, 551-555 (2005).
242. Knoferle, J. et al. Apolipoprotein E4 produced in GABAergic interneurons causes learning and memory deficits in mice. J. Neurosci. 34, 14069-14078 (2014).
243. Buckner, R. L. et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J. Neurosci. 25, 7709-7717 (2005).
244. Axelman, K., Basun, H., Winblad, B. & Lannfelt, L. A large Swedish family with Alzheimer's disease with a codon 670/671 amyloid precursor protein mutation: a clinical and genealogical investigation. Arch. Neurol. 51, 1193-1197 (1994).
245. Godbolt, A. K. et al. A second family with familial AD and the V717L APP mutation has a later age at onset. Neurology 66, 611-612 (2006).
246. Abe, M. et al. Phenotypical difference of amyloid precursor protein (APP) V717L mutation in Japanese family. BMC Neurol. 12, 38 (2012).
247. Kennedy, A. M. et al. Familial Alzheimer's disease. A pedigree with a mis-sense mutation in the amyloid precursor protein gene (amyloid precursor protein 717 valineglycine). Brain 116, 309-324 (1993).
248. Mullan, M. et al. Clinical comparison of Alzheimer's disease in pedigrees with the codon 717 ValIle mutation in the amyloid precursor protein gene. Neurobiol. Aging 14, 407-419 (1993).
249. Lindquist, S. G. et al. Atypical early-onset Alzheimer's disease caused by the Iranian APP mutation. J. Neurol. Sci. 268, 124-130 (2008).
250. Edwards-Lee, T. et al. An African American family with early-onset Alzheimer disease and an APP (T714I) mutation. Neurology 64, 377-379 (2005).
251. Sleegers, K. et al. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain 129, 2977-2983 (2006).
252. Remes, A. M. et al. Hereditary dementia with intracerebral hemorrhages and cerebral amyloid angiopathy. Neurology 63, 234-240 (2004).
253. Rovelet-Lecrux, A. et al. APP locus duplication in a Finnish family with dementia and intracerebral haemorrhage. J. Neurol. Neurosurg. Psychiatry 78, 1158-1159 (2007).
254. Axelman, K., Basun, H. & Lannfelt, L. Wide range of disease onset in a family with Alzheimer disease and a His163Tyr mutation in the presenilin1 gene. Arch. Neurol. 55, 698-702 (1998).
255. Mangone, C. A. et al. Early onset Alzheimer's disease in a South American pedigree from Argentina. Acta Neurol. Scand. 91, 6-13 (1995).
256. Mann, D. M. A. et al. Amyloid angiopathy and variability in amyloid deposition is determined by mutation position in presenilinlinked Alzheimer's disease. Am. J. Pathol. 158, 2165-2175 (2001).
257. Frommelt, P., Schnabel, R., Kuhne, W., Nee, L. E. & Polinsky, R. J. Familial Alzheimer disease: a large, multigeneration German kindred. Alzheimer Dis. Assoc. Disord. 5, 36-43 (1991).
258. Vossel, K. A. et al. Incidence and impact of subclinical epileptiform activity in alzheimer's disease. Ann. Neurol. http://dx.doi.org/10.1002/ana.24794 (2016).